Luye Pharma Group Stock Today
| LYPHF Stock | USD 0.34 0.03 9.68% |
Performance9 of 100
| Odds Of DistressOver 55
|
Luye Pharma is trading at 0.34 as of the 22nd of November 2024. This is a 9.68 percent increase since the beginning of the trading day. The stock's lowest day price was 0.34. Luye Pharma has over 55 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Luye Pharma Group are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Luye Pharma Group Ltd. develops, produces, markets, and sells pharmaceutical products worldwide. The company was founded in 1994 and is headquartered in Yantai, the Peoples Republic of China. Luye Pharma is traded on OTC Exchange in the United States. The company has 3.55 B outstanding shares. More on Luye Pharma Group
Moving against Luye Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Luye Pink Sheet Highlights
| CoFounder Chairman | Rong Yang |
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Luye Pharma Group [LYPHF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Luye Pharma's market, we take the total number of its shares issued and multiply it by Luye Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Luye Pharma Group classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 3.55 B outstanding shares.
Luye Pharma generates positive cash flow from operations, but has no cash available
Check Luye Pharma Probability Of Bankruptcy
Ownership AllocationLuye Pharma Group maintains a total of 3.55 Billion outstanding shares. Luye Pharma Group holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Luye Ownership Details
Luye Pharma Group Risk Profiles
| Mean Deviation | 0.3023 | |||
| Standard Deviation | 1.22 | |||
| Variance | 1.49 | |||
| Risk Adjusted Performance | 0.0998 |
Luye Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Luye Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
Luye Pharma Corporate Executives
Elected by the shareholders, the Luye Pharma's board of directors comprises two types of representatives: Luye Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Luye. The board's role is to monitor Luye Pharma's management team and ensure that shareholders' interests are well served. Luye Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Luye Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Other Information on Investing in Luye Pink Sheet
Luye Pharma financial ratios help investors to determine whether Luye Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Luye with respect to the benefits of owning Luye Pharma security.